Ozanimod - Isotope Labelled Standards
References
FAQ's
References
- Scott, F. L.; Clemons, B.; Brooks, J.; Brahmachary, E.; Powell, R.; Dedman, H.; Desale, H. G.; Timony, G. A.; Martinborough, E.; Rosen, H.; et al, Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity, British Journal of Pharmacology, Volume: 173, Issue: 11, Pages: 1778-1792, 2016 DOI: (10.1111/bph.13476)
- Martinborough, Esther; Boehm, Marcus F.; Yeager, Adam Richard; Tamiya, Junko; Huang, Liming; Brahmachary, Enugurthi; Moorjani, Manisha; Timony, Gregg Alan; Brooks, Jennifer L.; Peach, Robert; et al, Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis, WO2011060392A1, May 19, 2011, Receptos, Inc., United States
Frequently Asked Questions
What is the source of the presence of Ozanimod impurities in the drug?
Unreacted starting materials, residual solvents, and intermediates are the source of Ozanimod impurities in the drug.
How are Ozanimod impurities detected and quantified?
Ozanimod impurities are detected and quantified using analytical methods such as HPLC and LC-MS.
Which guidelines control potential Ozanimod impurities?
ICH Q3A and Q3C guidelines control potential Ozanimod impurities.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.